Ridofranz/iStock via Getty Images2seventy bio, Inc. (NASDAQ:TSVT) is a biotechnology company that develops and distributes Abecma (idecabtagene vicleucel). This is an FDA-approved CAR T cell therapy for multiple myeloma [MM], targeting the B-cell maturation antigen [BCMA]. Abecma has significantly advanced MM treatment and received an FDA extension for relapsed and refractory cases after at least two prior therapies [rrMM]. TSVT seems focused on Abecma now, which has pros and cons. However, I think its  ...